BIOVENTUS CLASS A INC

Bioventus reported Q2 revenue of $153 million, up 4%, adjusted EBITDA of $35 million and adjusted EPS of $0.22, driven by double‑digit growth in Pain Treatments led by DUROLANE. Management highlighted momentum in PRP, PNS and Ultrasonics, strong international pipeline, and continued cash generation with $20 million operating cash flow and additional $24 million debt repayment, bringing net leverage below 2x. The board has launched a strategic review after receiving multiple expressions of interest and an unsolicited acquisition proposal, while reaffirming full‑year guidance of $600–610 million revenue, $0.75–0.79 adjusted EPS and $84–89 million cash from operations. » Więcej na finance.yahoo.com

Bioventus reported Q2 revenue of $153 million (up 4%), adjusted EBITDA of $35 million and adjusted EPS of $0.22, driven by 12% growth in Pain Treatments led by DUROLANE. The company reaffirmed 2026 guidance of $600–$610 million in revenue and $0.75–$0.79 in adjusted EPS, and expects stronger second-half growth from PRP, PNS and Ultrasonics. The board formed an independent committee, advised by Evercore, to evaluate strategic alternatives after receiving acquisition interest including an unsolicited proposal. Bioventus reduced debt by $24 million in the quarter, bringing net leverage below 2x and targeting below 1.5x by year-end. » Więcej na finance.yahoo.com

Bioventus's stock climbed intraday by up to 13% and reached the year's highest level after the Centers for Medicare & Medicaid Services withdrew previously decided cuts to reimbursement for non-invasive bone growth stimulators. The price jump followed directly on the agency's announcement to rescind the cost reductions. » Więcej na de.investing.com